Biofrontera Inc. Completes Transfer of Ameluz® and RhodoLED® FDA approval and Associated Intellectual Property Portfolio

Core Insights - Biofrontera Inc. has successfully transferred the New Drug Application (NDA) and Investigational New Drug Application (IND) for Ameluz and the RhodoLED Lamp Series, allowing the company to independently manage clinical development and marketing in the US [1][2] - The transfer includes 11 granted US patents, 10 pending US patent applications, and 19 international patent applications related to the products, enhancing Biofrontera's intellectual property portfolio [1][2] - The completion of these transfers is seen as a significant milestone in Biofrontera's strategy to optimize operations and pursue new clinical indications for its products [3] Company Overview - Biofrontera Inc. is a biopharmaceutical company focused on photodynamic therapy (PDT) for dermatological conditions, particularly Actinic Keratosis and other skin lesions [4] - The company aims to expand the use of its products to treat non-melanoma skin cancers and moderate to severe acne through ongoing clinical trials [4]